APA
Seymour J. F., Marcus R., Davies A., Gallop-Evans E., Grigg A., Haynes A., Herold M., Illmer T., Nilsson-Ehle H., Sökler M., Dünzinger U., Nielsen T., Launonen A. & Hiddemann W. (20200518). Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. : Haematologica.
Chicago
Seymour John F, Marcus Robert, Davies Andrew, Gallop-Evans Eve, Grigg Andrew, Haynes Andrew, Herold Michael, Illmer Thomas, Nilsson-Ehle Herman, Sökler Martin, Dünzinger Ulrich, Nielsen Tina, Launonen Aino and Hiddemann Wolfgang. 20200518. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. : Haematologica.
Harvard
Seymour J. F., Marcus R., Davies A., Gallop-Evans E., Grigg A., Haynes A., Herold M., Illmer T., Nilsson-Ehle H., Sökler M., Dünzinger U., Nielsen T., Launonen A. and Hiddemann W. (20200518). Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. : Haematologica.
MLA
Seymour John F, Marcus Robert, Davies Andrew, Gallop-Evans Eve, Grigg Andrew, Haynes Andrew, Herold Michael, Illmer Thomas, Nilsson-Ehle Herman, Sökler Martin, Dünzinger Ulrich, Nielsen Tina, Launonen Aino and Hiddemann Wolfgang. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. : Haematologica. 20200518.